» Authors » Fatemeh Bandarian

Fatemeh Bandarian

Explore the profile of Fatemeh Bandarian including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 91
Citations 510
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohammadi-Khanaposhtani M, Bahrami T, Bandarian F, Nasli-Esfahani E, Roostaei D, Zamani E, et al.
J Diabetes Metab Disord . 2025 Feb; 24(1):67. PMID: 39959578
Objectives: The in vivo assay is a key step in the development of a new compound as a drug. In the present work, bis-4-aminocoumarin derivative 3,3'-(p-tolylmethylene)bis(4-amino-2H-chromen-2-one) () and bis-4-hydroxycoumarin derivative...
2.
Soltani A, Aghakhani A, Dehghanbanadaki H, Majidi Z, Rezaei-Tavirani M, Shafiee G, et al.
J Diabetes Metab Disord . 2025 Feb; 24(1):65. PMID: 39927178
Objectives: Both liver fibrosis and osteoporosis share inflammatory pathways, with liver fibrosis potentially contributing to decreased bone mineral density (BMD). The rising prevalence of non-alcoholic fatty liver disease (NAFLD) and...
3.
Bandarian F, Razi F, Razzaghi Z, Rostami-Nejad M, Arjmand B, Ahmadzadeh A
Asian Pac J Cancer Prev . 2024 Nov; 25(11):4035-4041. PMID: 39611928
Objective: Glioblastoma, previously recognized as glioblastoma multiform (GBM), is the most aggressive and most common type of cancer that originates in the brain and has a very poor prognosis for...
4.
Mansouri V, Bandarian F, Razi F, Razzaghi Z, Rezaei-Tavirani M, Rezaei M, et al.
J Diabetes Metab Disord . 2024 Nov; 23(2):2021-2030. PMID: 39610517
Introduction: Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects...
5.
Mohammadi-Khanaposhtani M, Bakhtiari N, Bandarian F, Larijani B, Mahdavi M, Najafzadehvarzi H
J Diabetes Metab Disord . 2024 Nov; 23(2):2375-2384. PMID: 39610500
Objectives: The assay is a key step in the development of a new bioactive compound as a lead drug structure. Based on importance of α-glucosidase inhibitors in the control of...
6.
Esmaeili S, Bandarian F, Razi F, Adibi H, Jalili A, Arjmand B, et al.
J Diabetes Metab Disord . 2024 Nov; 23(2):1809-1816. PMID: 39610497
Background: Endocrinology and Metabolism Research Institute (EMRI) is one of the biggest research institutes in Iran that was established to develop research strategies for managing endocrine and metabolic disorders such...
7.
Hosseinkhani S, Arjmand B, Bandarian F, Aazami H, Hadizadeh N, Najjar N, et al.
J Diabetes Metab Disord . 2024 Nov; 23(2):1539-1544. PMID: 39610495
Objective: The aim of this study was to evaluate the status of scientific research output of omics in regards to human diseases with more attention shifted toward endocrine and metabolism...
8.
Peimani M, Esfahani Z, Bandarian F, Esmaeili S, Moghaddam S, Namazi N, et al.
Iran J Public Health . 2024 Oct; 53(4):913-923. PMID: 39444467
Background: This study presents estimates for type 2 diabetes mellitus (T2DM) burden and attributable risk factors in Iran from 1990-2019, using data from the 2019 Global Burden of Disease study....
9.
Hussein S, Bandarian F, Salehi N, Mosadegh Khah A, Motevaseli E, Azizi Z
Cureus . 2024 Oct; 16(9):e68611. PMID: 39371824
Background Type 1 diabetes (T1D) is an autoimmune disorder that results in the destruction of pancreatic beta cells, causing a shortage of insulin secretion. The development of T1D is influenced...
10.
Rostami Nejad M, Bandarian F, Razi F, Razzaghi Z, Robati R, Rezaei M, et al.
J Lasers Med Sci . 2024 Aug; 15:e33. PMID: 39193105
Intensity is one of the important parameters of laser radiation in photodynamic therapy. Effective treatment requires the selection of a suitable power of laser. This study aimed to evaluate laser...